Methods	Randomised, double-blind, placebo-controlled, parallel-group, partial enrichment. No imputation method mentioned Titration to pain ≤ 3/10 or limit of tolerability, or maximum 1800 mg daily (10 days in total)
Participants	Neuropathic cancer pain despite regular systemic opioid therapy. N = 121, mean age 60 years, 56% women. Pain at randomisation ≥ 5/10, initial pain intensity 7.3/10
Interventions	Gabapentin 1800 mg daily (max), n = 80 Placebo, n = 41 Any previous analgesics continued unchanged. One additional dose of opioid allowed for rescue medication
Outcomes	No dichotomous efficacy data Adverse events Withdrawals
Notes	Oxford Quality Score: R = 2, DB = 2, W = 1, Total = 5
Risk of bias
Item	Authors’ judgement	Description
Allocation concealment?	Yes	Remote pharmacy department provided numbered containers
Blinding? All outcomes	Yes	“identical capsules”
Incomplete outcome data addressed? Efficacy	Unclear	Imputation not mentioned
Size Efficacy	Unclear	121 randomised
Study duration Efficacy	No	10 days
Outcomes reported	No	No dichotomous outcomes